Prostate cancer represents an ideal target for radioimmunotherapy based on the pattern of
spread, including bone marrow and lymph nodes, sites that typically receive high levels of
circulating antibody, and the small volume of disease, ideally suited for antibody delivery
and antigen access. This review explores possible antibody targets in prostate cancer and
focuses on the potential role for radioimmunotherapy by highlighting several clinical trials
involving radiolabeled anti–prostatespecific membrane antigen monoclonal antibody J591 …